ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
In silico and in vitro insights into stigmasterol targeting Keap1/Nrf2, Bcl-2/Bax and IKKβ/IκBα protein-protein interactions in Arsenic-induced toxicity.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Inorganic arsenic is a known neurotoxin that contributes to neurodevelopmental and neurodegenerative disorders by promoting oxidative stress, mitochondrial dysfunction and inflammation. It crosses the blood-brain barrier and accumulates in brain tissue. Arsenic-induced neurotoxicity poses a significant health challenge, driving the need for multi-targeted therapeutic agents. This study investigated the neuroprotective potential of stigmasterol, a plant-derived phytosterol, against arsenic-induced damage in mouse HT-22 hippocampal cells through integrated computational and experimental approaches. Molecular docking and dynamics simulations revealed that stigmasterol disrupts the Keap1-Nrf2 complex (E-total, - 346 kJ/mol), and may promote Nrf2 activation and antioxidant gene expression. It stabilizes the Bcl-2/Bax complex (E-total, - 540 kJ/mol), enhancing anti-apoptotic signaling, and strengthens the IKKβ/IκBα interaction (E-total, - 687 kJ/mol), inhibiting NF-κB-mediated inflammation. In vitro assays confirmed that stigmasterol protected the cells in dose-dependent manner, restoring cell viability up to ~ 81%, and significantly reduced ROS levels compared to arsenic-treated cells. Neuronal morphology analysis further confirmed stigmasterol's ability to preserve neurite integrity and cellular connectivity against arsenic-induced damage. These findings highlight the multi-faceted neuroprotective mechanisms of stigmasterol in an in vitro neuronal model and suggest its potential role in mitigating arsenic-induced neuronal damage, which requires further validation through in vivo and pharmacological studies.
Indexed as
Identifiers
41999429What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.